Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation

Clinical Transplantation

Volumn 19, Issue 5, 2005, Pages 638-643

  Zhang, Xin ^a   Liu, Zhi Hong ^a   Zheng, Jing Min ^a   Chen, Zhao Hong ^a   Tang, Zheng ^a   Chen, Jin Song ^a   Li, Lei Shi ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

CYP3A5; Gene polymorphism; MDR1; Pharmacokinetics; Tacrolimus

Indexed keywords

CYTOCHROME P450 3A5; GLYCOPROTEIN P; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MULTIDRUG RESISTANCE PROTEIN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS;

ADULT; ALLELE; ARTICLE; CALCULATION; CHINESE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG METABOLISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ABSORPTION; ADULT; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; GENETIC MARKERS; GENOTYPE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; TACROLIMUS; TIME FACTORS;

EID: 25144457116     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2005.00370.x     Document Type: Article

References (23)

1. Spencer CM, Goa KL, Gillis JC. Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation. Drugs 1997: 54: 925.
2. Lampen A, Christians U, Guengerich FP et al. Metabolism of the imumnosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. Drug Metab Dispos 1995: 23: 1315.
3. Sattler M, Guengerich FP, Yun CH. Christians U, Sewing KF. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos 1992: 20: 753.
4. Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 1998: 38: 389.
5. Kuehl P, Zhang J, Lin Y et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001: 27: 383.
6. Saeki T, Ueda K, Tanigawara Y et al. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 1993: 268: 6077.
7. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A 1987: 84: 7735.
8. Fredericks S, Holt DW. Pharmacogenomics of immunosuppressive drug metabolism. Curr Opin Nephrol Hypertens 2003: 12: 607.
9. Hebert MF. Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv Drug Deliv Rev 1997: 27: 201.
10. Zhang Y, Benet LZ. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 2001: 40: 159.
11. Hoffmeyer S, Burk O, Von Richter O et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000: 97: 3473.
12. Zheng H, Webber S, Zeevi A et al. Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am J Transplant 2003: 3: 477.
13. Hesselink DA, van der Schaik RH, van Heiden IP et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003: 74: 245.
14. Thervet E, Anglicheau D, King B et al. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 2003: 76: 1233.
15. Zheng H, Zeevi A, Schuetz E et al. Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism. J Clin Pharmacol 2004: 44: 135.
16. Haufroid V, Mourad, M, van Kerckhove V et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 2004: 14: 147.
17. Tsuchiya N, Satoh S, Tada H et al. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation 2004: 78: 1182.
18. MacPhee IA, Fredericks S, Tai T et al. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 2002: 74: 1486.
19. Anglicheau D, Verstuyft C, Laurent-Puig P et al. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol 2003: 14: 1889.
20. Van Schaik RH, van der Heiden IP, van den Anker JN, Lindemans J. CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem 2002: 48: 1668.
21. Calado RT, Falcao RP, Garcia AB et al. Influence of functional MDR1 gene polymorphisms on P-glycoprotein activity in CD34+ hematopoietic stem cells. Haematologica 2002: 87: 564.
22. Venkataramanan R, Swaminathan A, Prasad T et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 1995: 29: 404.
23. MacPhee IA, Fredericks S, Tai T et al. The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am J Transplant 2004: 4: 914.